NEW YORK – Revvity and Danaher subsidiary Sciex said Tuesday that they have signed a distribution agreement that will improve the accuracy of mass spectrometry-based disease screening in newborns by combining Sciex's mass spectrometry instruments and Revvity's reagents.
The Massachusetts-based firms said they will collaborate to use Revvity's NeoBase 2 and NeoLSD MSMS reagent kits with Sciex's mass specs for newborn screening tests. This will help laboratories improve the precision and robustness of mass spectrometry screening methods to identify diseases including lysosomal storage disorders and amino acid disorders, they added.
Financial and other terms of the deal were not disclosed.
Revvity's NeoBase 2 non-derivatized MSMS kit is used to measure more than 50 analytes, including markers for X-linked adrenoleukodystrophy and adenosine deaminase severe combined immunodeficiency. The firm's NeoLSD MSMS kit is used to screen for lysosomal storage disorders, Gaucher disease, Niemann-Pick A/B disease, Pompe disease, Krabbe disease, Fabry disease, and MPS I disease. Both use dried blood spot samples.
"Revvity is committed to advancing newborn screening and helping give babies a better start in life," Petra Furu, Revvity's general manager for reproductive health, said in a statement. "This capability will help provide our customers with the best options for their expanded screening programs by combining precise instrumentation with groundbreaking reagents."